Rallybio Corporation
RLYB
$16.99
$0.030.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -15.11% | 1.18% | 34.91% | 12.71% | 154.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.11% | 1.18% | 34.91% | 12.71% | 154.52% |
| Cost of Revenue | -46.40% | -65.06% | -62.30% | -66.97% | -62.39% |
| Gross Profit | 47.64% | 66.84% | 63.97% | 67.97% | 63.62% |
| SG&A Expenses | 5.19% | -0.58% | -15.86% | -25.69% | -27.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.30% | -32.64% | -37.79% | -47.05% | -45.00% |
| Operating Income | 32.62% | 33.25% | 38.65% | 47.59% | 45.81% |
| Income Before Tax | 212.54% | 83.78% | 84.46% | 78.84% | 43.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 209.36% | 83.78% | 84.46% | 78.84% | 43.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 209.36% | 83.78% | 84.46% | 78.84% | 43.62% |
| EBIT | 32.62% | 33.25% | 38.65% | 47.59% | 45.81% |
| EBITDA | 32.53% | 33.22% | 38.67% | 47.66% | 45.86% |
| EPS Basic | 207.62% | 84.16% | 85.03% | 79.93% | 47.84% |
| Normalized Basic EPS | 163.49% | 35.46% | 41.23% | 50.88% | 49.37% |
| EPS Diluted | 205.85% | 84.16% | 85.03% | 79.93% | 47.84% |
| Normalized Diluted EPS | 161.55% | 35.46% | 41.23% | 50.88% | 49.37% |
| Average Basic Shares Outstanding | 1.54% | 1.52% | 3.44% | 5.41% | 7.71% |
| Average Diluted Shares Outstanding | 1.98% | 1.52% | 3.44% | 5.41% | 7.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |